During the COVID-19 pandemic, the U.S. Food and Drug Administration (FDA) approved and Authorized various vaccines, antivirals, and monoclonal antibody therapies to prevent and treat people infected with the SARS-CoV-2 coronavirus that causes COVID-19.
COVID-19 Vaccines in the U.S.
The U.S. FDA Approved COVID-19 vaccines and issued various Emergency Use Authorizations. The initial FDA Approval was for the Pfizer-BioNTech Comirnaty™ vaccine on August 23, 2021, followed by Moderna's SpikeVax™ vaccine on February 4, 2022. And the FDA Authorized the Jcovden COVID-19 vaccine on February 27, 2021. Then on July 13, 2022, the FDA Authorized the Novavax COVID-19 Vaccine (Nuvaxovid™, NVX-CoV2373).
On January 26, 2023, the FDA's Vaccines and Related Biological Products Advisory Committee is review this Briefing Document.
COVID-19 Vaccine Meetings
The U.S. FDA's Advisory Committee meeting (Docket # FDA-2022-N-2810.) on January 26, 2023, published an Executive Briefing document.
And the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) presented the following information on February 24, 2023: Introduction, Dr. Matthew Daley; COVID-19 vaccine safety updates: CDC, Dr. Tom Shimabukuro; COVID-19 vaccine safety updates: FDA, Dr. Richard Forshee; VaST summary, Dr. Keipp Talbot; WG interpretation and summary, Dr. Evelyn Twentyman; Updates on COVID-19 hospitalizations: COVID-NET, Dr. Chris Taylor; Updates to COVID-19 vaccine effectiveness in the United States, Dr. Amadea Britton; Considerations for transitioning to bivalent primary series, Dr. Sara Oliver; Benefit/risk for COVID-19 vaccines, Dr. Megan Wallace; COVID-19 vaccines: future directions, Dr. Sara Oliver.
Previously, on October 20, 2022, the ACIP members unanimously voted to expand the 2023 vaccination schedules. The ACIP reviewed the following presentations led by Dr. Grace Lee. On October 19, 2022, the CDC recommended using the Novavax COVID-19 Vaccine, Adjuvanted, as a booster for adults. And on September 13, 2022, the CDC's Clinician Outreach and Communication Activity Call reviewed: Recommendations for Bivalent COVID-19 Booster Doses in People Ages 12 Years and Older.
COVID-19 Vaccination in the UK for 2023
The UK's Joint Committee on Vaccination and Immunisation published a statement regarding 2023 COVID-19 vaccination program recommendations for 2023 and a related Independent Report analysis on January 25, 2023.
COVID-19 Vaccines International
The World Health Organization (WHO) has Listed various COVID-19 vaccines. On March 28, 2023, the WHO's Strategic Advisory Group of Experts on Immunization revised the roadmap for prioritizing the use of COVID-19 vaccines, to reflect the impact of Omicron and high population-level immunity due to infection and vaccination.
In addition, the WHO publishes an analytic report produced by the COVID-19 Vaccine Delivery Partnership of COVID-19 vaccine data, including 1) daily vaccination rate, 2) population coverage, 3) supply secured & received, and 4) product utilization data across COVAX AMC portfolio and CoVDP's Countries for Concerted Support. And the European Medicines Agency (EMA) has Authorized various COVID-19 vaccines as of December 2022.
Vaccine Adverse Event Reporting System
The Vaccine Adverse Event Reporting System is passive, meaning it relies on individuals to send in reports of their experiences. Anyone, including parents and patients, can submit a vaccine side effect report to VAERS. Search vaccines.gov, text your zip code to 438829, or call 1-800-232-0233 to find COVID-19 vaccine, antivirals, or antibody locations, such as pharmacies.